Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of Lapatinib plus Capecitabine versus Capecitabine alone as radiosensitizers in KRAS wild-type resectable rectal cancer
2013-001203-36Phase 2Active
- Sponsor
- Instituto Português de Oncologia do Porto
- Start
- Dec 2013
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in rectal cancer comparing Lapatinib + Capecitabine + Radiation therapy with Capecitabine + Radiation therapy (2 arms). Primary endpoint: pathologic complete remission. Started Dec 2013; status: active.
02
Drugs
lapatinibcapecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on 2013-001203-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001203-36.